LifeMD is a New York virtual-care and pharmacy platform that just finished walking away from compounded weight-loss drugs, and the equity now prices that cleanup as a broken growth story rather than a completed mix reset. The investment debate is whether a branded, longer-duration subscriber book plus an in-house pharmacy can restore profit after management cut the year and missed its own earnings target. Shares sit near $3, a long way below last year's peak, because the market treats the second-half rebound as optional rather than earned. That gap between a cleaner book and a cheaper multiple is the entire case.
The most important development is the compounded-to-branded handoff inside Weight Management. Roughly 95% of new patients now start on manufacturer therapies rather than compounded copies, which removes a regulatory overhang but also removes the cheap, high-upfront cash that used to fund paid-media growth. Management paired that mix shift with a pricing change that pushed multi-month packages from about 25% of new starts toward 85%. That is a better book on paper. It is also why second-quarter revenue of $47 million sat inside the guided band while adjusted earnings swung to a loss. Gross margin still expanded, which tells the reader the product engine is not the problem. Acquisition cost and collection timing are.
The tension is that the cleanup already forced one large guidance cut, and the company has a recent habit of raising then lowering the year. Cash fell from about $37 million at year-end to $25 million by June, operating cash turned negative, and a perpetual preferred still takes a quarterly coupon off the residual. A securities complaint styled Johnston still sits over last year's guidance episode. The bull case treats the second half as a mechanical rebound once marketing steps down and rebills stack. The stronger counterargument is that paid-search auctions, branded-drug affordability, and a second consecutive outlook reset make the fourth-quarter exit run rate a hope, not a base.
The next test is the third-quarter print against a narrow revenue band and a return toward break-even adjusted earnings. If that print lands and cash stops falling, the year-end step-up becomes believable. If it does not, the remaining cash and the preferred claim start to dominate the common. That is the clock on this equity, and it is already running.